Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from the Phase III CheckMate-816 study for its Opdivo (nivolumab) in patients with resectable non-small cell lung cancer (NSCLC).
Study Highlights
The CheckMate-816 study evaluated Opdivo in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable NSCLC (tumors ≥ 4 cm or node positive). Results demonstrated a statistically significant and clinically meaningful improvement in OS, a key secondary endpoint, compared to neoadjuvant chemotherapy alone. Previously, the study also met primary endpoints of event-free survival (EFS) and pathological complete response (pCR).-Fineline Info & Tech
Leave a Reply